On a Wednesday in early September, shares of Vera Therapeutics, a clinical-stage biotechnology company developing treatments for serious immune diseases, traded near $22.61, far beneath the $63.00 average target that its ten covering analysts have set. The gap is a familiar human tension: a young company betting its future on a single lead drug, atacicept, while the market waits to see whether patience will be rewarded. Its latest quarterly loss, larger than expected, has tested that patience, even as one director quietly bought stock in June and the analysts' consensus still leans toward opti
Vera Therapeutics (VERA) Carries 'Moderate Buy' Consensus as Analysts Average $63 Target
A $63 average target, and a stock opening at $22.61
Mark
The headline says Moderate Buy with a $63 target, but the stock is at $22.61. Why is the gap so large?
Mimi
The target is an average of what analysts think the shares could be worth in twelve months. The price is where they trade now. For a clinical-stage biotech, the distance usually reflects how much the outcome of the trials matters.
Luke
Careful, though. The article doesn't explain the gap. It reports the numbers, not the reasoning behind them.
Mark
Fair. What do the individual calls show?
Mimi
They vary. HC Wainwright raised its target to $85 from $75. Wedbush cut to $26 from $34 and is neutral. Wolfe has a peer perform rating.
Luke
And most of those dates are May and June. Only Wolfe's is after the August earnings report. So the $63 average may not yet reflect that miss.
Mark
The miss was $1.20 per share against an expected $0.82 loss. How bad is that?
Mimi
It's a wider loss than forecast, and a year ago the loss was $0.62. But the balance sheet shows a current ratio of 17.03 and low debt.
Luke
Which says the company is liquid. It doesn't say how long the cash lasts. That figure isn't in the piece.
Mark
What about the director's purchase?
Mimi
Patrick Enright bought 40,607 shares at $22.35, about $907,566, in June. It's a real signal of confidence from an insider.
Luke
It is, but it's one purchase from one director, and it happened before the earnings report. I wouldn't read more into it than that.
El Pulso
- Vera Therapeutics shares opened near $22.61, sitting far below an average analyst target of $63.00.
- The August earnings report delivered a loss of $1.20 per share, missing the expected $0.82 loss and widening the doubt.
- Analysts still lean toward buying, with seven buy ratings, one strong buy, and two holds, though Wedbush has already cut its target to $26.00.
- A director's purchase of roughly $907,566 in stock offers a signal of insider confidence amid the sell-off.
- Attention now turns to whether analysts will lower their targets to match the company's current losses and trading reality.
On a Wednesday in early September, shares of Vera Therapeutics, a clinical-stage biotechnology company developing treatments for serious immune diseases, traded near $22.61, far beneath the $63.00 average target that its ten covering analysts have set. The gap is a familiar human tension: a young company betting its future on a single lead drug, atacicept, while the market waits to see whether patience will be rewarded. Its latest quarterly loss, larger than expected, has tested that patience, even as one director quietly bought stock in June and the analysts' consensus still leans toward optimism. What happens next depends on whether the people who have studied the company revise their hopes in light of the disappointing numbers.
Vera Therapeutics opened at $22.61 a share on Wednesday, September 3rd, while the ten firms that follow it set an average twelve-month target of $63.00. Their consensus is a "Moderate Buy," with seven buy ratings, one strong buy, and two holds. The company is a clinical-stage biotech that develops treatments for serious immune diseases. Its lead candidate, atacicept, is a self-administered injection now in Phase III trials for immunoglobulin A nephropathy and in Phase II for lupus nephritis.
The individual calls vary widely. HC Wainwright raised its target from $75.00 to $85.00 and reaffirmed a buy in June, while Wedbush cut its target from $34.00 to $26.00 and went neutral in May. The August quarterly report was weak: a loss of $1.20 per share against an expected $0.82 loss. Analysts expect a loss of $2.89 per share for the year.
The stock has ranged between $18.53 and $51.61 over the past year, and its market value is about $1.44 billion. Its balance sheet is sturdy, with a debt-to-equity ratio of 0.16. In June, director Patrick G. Enright bought 40,607 shares at about $22.35, a $907,566 purchase that lifted his holdings to roughly 3.6 million shares. Institutions own 99.21% of the company, though recent fund moves have been small.
The open question is whether analysts will adjust their targets after the earnings miss, since most of their reiterated ratings predate the August report.
Vera Therapeutics opened at $22.61 a share on Wednesday, September 3rd. The ten firms that cover the stock, by contrast, put its average 12-month target at $63.00. According to MarketBeat, that gap sits beneath a consensus rating of "Moderate Buy." Seven analysts rate the stock a buy, one rates it a strong buy, and two say hold.
Vera is a clinical-stage biotechnology company that develops treatments for serious immunological diseases. Its lead candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. It is in Phase III trials for immunoglobulin A nephropathy and in Phase II for lupus nephritis.
The individual analyst calls vary widely. HC Wainwright reaffirmed a buy rating on Monday, June 2nd, and raised its target from $75.00 to $85.00. Scotiabank reissued an outperform rating on June 3rd, and Guggenheim reaffirmed a buy the same day. Wolfe Research held to a peer perform rating on Monday, August 4th. Wedbush is the most cautious of the five. On Wednesday, May 7th, it cut its target from $34.00 to $26.00 and set a neutral rating.
The company's most recent quarterly report, on Tuesday, August 5th, was weak. Vera posted a loss of $1.20 per share against a consensus estimate of a $0.82 loss, a miss of $0.38. In the same quarter a year earlier, the loss was $0.62 per share. Analysts expect a loss of $2.89 per share for the current fiscal year.
The stock's recent trading reflects that gap. The 50-day moving average is $22.19 and the 200-day is $23.47. Over the past twelve months, shares have ranged from a low of $18.53 to a high of $51.61. Market capitalization is $1.44 billion. The balance sheet looks sturdy: a debt-to-equity ratio of 0.16 and both current and quick ratios of 17.03.
One insider has been buying. On Tuesday, June 24th, director Patrick G. Enright purchased 40,607 shares at an average of $22.35, for a total of $907,566.45. He now directly holds 3,596,593 shares, worth roughly $80.4 million at that price. The purchase raised his holdings by 1.14%, and it was disclosed in a filing with the Securities and Exchange Commission. Corporate insiders as a group own 16.30% of the company.
Institutions hold 99.21% of the stock, and recent filings show small moves. GF Fund Management opened a position valued at $56,000 in the fourth quarter, and Quantbot Technologies opened one valued at $51,000 in the second quarter. Quarry LP added 500 shares, a 25.0% increase, bringing it to 2,500 shares worth $60,000. AlphaQuest raised its stake by 404.7% to 4,007 shares worth $96,000. Virtus Investment Advisers added 539 shares, up 14.8%, for 4,176 shares worth $98,000. None of these positions is large.
What to watch next is whether analysts adjust their targets after the earnings miss. Most of the reiterated ratings predate the August report.
Citas Notables
Reaffirmed a buy rating and raised its target price from $75.00 to $85.00.— HC Wainwright, research report, June 2
Quieres la nota completa?
Lee el original en ETF Daily News ↗
Economy & Finance